CLOs on the Move

Tearlab

www.tearlab.com

 
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tearlab.com
  • 9980 Huennekens St. Ste 100
    San Diego, CA USA 92121
  • Phone: 855.832.7522

Executives

Name Title Contact Details

Similar Companies

Intelerad

Improving healthcare through innovative technology is at the core of Intelerad`s work. Our scalable medical imaging platform connects clinicians to a powerful imaging ecosystem that is fast, smart and tapped into the data they need, no matter their location. We`re focused on delivering a best-in-class medical image management solution that improves provider efficiency, decreases the cost of healthcare, and improves the overall health of populations.

Genesis Medical Imaging

Genesis Medical Imaging, Inc. is a Huntley, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

nova biomedical

nova biomedical is a Billerica, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rejuve

Rejuve is a Saratoga, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GenMark Diagnostics

In 1993, a novel technology was invented by a team that included Jon Faiz Kayyem, PhD at The California Institute of Technology (CalTech). This invention combined nucleic acids and microelectronics to produce an electronic sensor for DNA detection. His invention was based on electrical detection of nucleic acids on a cassette based detection platform. Dr. Kayyem went on to found Clinical Micro Sensors, with the goal of translating this “eSensor” technology to disposable chips. Following several acquisitions of the technology, Dr. Kayyem became actively involved again in 2009, returning as an investor and then as CEO and Chairman of the Board. In 2009, a collaboration between Dr. Kayyem and Christopher Gleeson began. The two redefined the company strategy, and brought in a new board of directors, executive leadership team, and commercial management. In 2010, the company known at that time as Osmetech, was named GenMark Diagnostics and listed on NASDAQ. Mr. Gleeson remained an integral part of GenMark`s growth in the years that followed, serving as Chairman of the Board until his retirement in 2014. Dr. Kayyem currently serves as SVP, Research and Development.